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2402 wileyonlinelibrary.com/journal/bphOver the past decades, research has defined cAMP as one of the central cellular nodes
in sensing and integrating multiple pathways and as a pivotal role player in lung patho-
physiology. Obstructive lung disorders, such as chronic obstructive pulmonary disease
(COPD), are characterized by a persistent and progressive airflow limitation and by oxi-
dative stress from endogenous and exogenous insults. The extent of airflow obstruc-
tion depends on the relative deposition of different constituents of the extracellular
matrix, a process related to epithelial‐to‐mesenchymal transition, and which subse-
quently results in airway fibrosis. Oxidative stress from endogenous and also from
exogenous sources causes a profound worsening of COPD. Here we describe how
cAMP scaffolds and their different signalosomes in different subcellular compartments
may contribute to COPD. Future research will require translational studies to alleviate
disease symptoms by pharmacologically targeting the cAMP scaffolds.
LINKED ARTICLES: This article is part of a themed section on Adrenoceptors—
New Roles for Old Players. To view the other articles in this section visit http://
onlinelibrary.wiley.com/doi/10.1111/bph.v176.14/issuetoc1 | INTRODUCTION
In this article, we highlight the most recent insights into the signalling
pathways regulated by cAMP, one of themost ancient and important sec-
ond messengers (Billington, Penn, & Hall, 2017). Novel aspects of cAMP
scaffolds, which are maintained by a diverse subset of proteins including
but not limited to receptors, exchange proteins, PDEs, and A‐- - - - - - - - - - - - - - - - - - - - - - - - - -
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, chronic obstructive pulmonary
‐mesenchymal transition; Epac,
n/radixin/moesin; IPF, idiopathic
ooth muscle actinkinase anchoring proteins (AKAPs), are also detailed. Our special focus is
on epithelial‐to‐mesenchymal transition (EMT) and oxidative stress
(Figure 1) in chronic obstructive pulmonary disease (COPD) and how
cAMP scaffolds may contribute to alleviation of COPD symptoms and
the potential role of these scaffolds in both health and disease conditions.2 | EPITHELIAL‐TO‐MESENCHYMAL
TRANSITION
The cAMP signalling pathway is one of the many pathways that are
implicated in EMT (Bartis, Mise, Mahida, Eickelberg, & Thickett,- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
onCommercial License, which permits use, distribution and reproduction in any
purposes.
ns Ltd on behalf of British Pharmacological Society.
Br J Pharmacol. 2019;176:2402–2415.
FIGURE 1 General outline of the epithelial‐to‐mesenchymal transition (EMT) and its potential link to cAMP scaffolds. The epithelial cell layer is
maintained by cell–cell contacts through tight and adherens junctions, desmosomes, and gap junctions. The epithelial cell phenotype is identified
by some known biomarkers, such as E‐cadherin, zonula occludens 1 (ZO‐1), cytokeratin, mucin 1, and laminin‐1. Transcription factors involved in
the EMT process belong to Snail family (snail1 and snail2), Zeb family (ZEB1 and ZEB2), and Twist family (twist1, twist2, and twist3). Mesenchymal
cell phenotype is characterized by α‐smooth muscle actin (α‐SMA), N‐cadherin, vimentin, type I collagen, fibronectin, and β‐catenin. For further
details, see text
ZUO ET AL. 2403BJP2014; Jansen, Gosens, Wieland, & Schmidt, 2018; Jolly, Ware, Gilja,
Somarelli, & Levine, 2017; Nieto, 2011). The EMT process comprises
the loss of cell–cell junctions (tight junctions, desmosomes, and
adherens junctions) and the loss of cell interactions with the basal
membrane. EMT also involves the loss of apicobasal polarity, the
change in cell shape from cuboidal to fibroblastoid, and the subse-
quent acquisition of migratory and invasive properties due to a loose
organized morphology as demonstrated on a three‐dimensional extra-
cellular matrix (ECM; López‐Novoa & Nieto, 2009; Nieto, 2011;
Oldenburger, Poppinga, et al., 2014; Thiery, Acloque, Huang, & Nieto,
2009). In order to characterize the EMT process, biomarkers including
the epithelial cell biomarkers E‐cadherin and zonula occludens 1
(ZO‐1) and the mesenchymal cell biomarkers α‐smooth muscle actin
(α‐SMA) and β‐catenin are used. Next to biomarkers, transcription fac-
tors including family members of Snail, Zeb, and Twist (Figure 1) are
also used to characterize the EMT process (Kalluri & Weinberg,
2009; Thiery et al., 2009).
TGF‐β1 is the best known inducer of EMT (Gonzalez & Medici,
2014; Lamouille, Xu, & Derynck, 2014). TGF‐β1 treatment of rat alveo-
lar epithelial cells increased expression of mesenchymal cell markers,
such as α‐SMA, type I collagen, vimentin, and desmin, whereas expres-
sion of epithelial markers aquaporin‐5, ZO‐1, and cytokeratin was
reduced (Willis et al., 2005). The central role of TGF‐β1 signalling in
the process of EMT is supported by its ability to induce its own expres-
sion and subsequently lead to an increase in its release following induc-
tion by a variety of growth factors and cytokines such as IL‐6 and IL‐8. It
is generally believed that these TGF‐β1‐driven, “feedforward” mecha-
nisms act in concert with a distinct subset of external cellular cues toefficiently regulate down‐regulation of epithelial markers and up‐
regulation of mesenchymal markers, which are crucial characteristics
of EMT (Tan, Olsson, & Moustakas, 2015). A process known as
mesenchymal‐epithelial transition (MET) is linked to the transition of
primary mesenchymal cells to secondary epithelial cells (Acloque,
Adams, Fishwick, Bronner‐Fraser, & Nieto, 2009).2.1 | Classification of the distinct stages of the EMT
process
Principally, three different types of EMT have been identified on the
basis of their distinct cellular phenotypes and responses (Kalluri &
Weinberg, 2009). Type I EMT is primarily linked to epithelial cell phe-
notypical alterations during gastrulation and embryonic formation, and
it is essentially characterized by transition of primitive epithelial cells
to primary mesenchymal cells (Kim et al., 2017). Type II EMT is asso-
ciated with a phenotypical change of secondary epithelial cells to
fibroblasts and is stimulated by damage and local inflammation, which
occurs primarily in mature tissue during tissue repair (wound healing),
tissue regeneration, and organ fibrosis. Type II EMT is characterized
by the ability of epithelial cells to migrate into interstitial spaces (Kim
et al., 2017; Zeisberg & Neilson, 2009). During tissue repair, inflamma-
tory stimuli such asTGF‐β, TNF‐α, and IL‐1β promote the formation of
fibroblasts in a process referred to as fibrosis. Fibrosis is characterized
by an excessive deposition of collagens, elastin, tenacin, and other
ECM molecules. Persistent inflammation therefore induces fibrosis
and permanent organ damage. Furthermore, type II EMT is not
2404 ZUO ET AL.BJPconfined to epithelial cells but also occurs in endothelial cells, indicat-
ing that this process is crucial for tissue repair (Agarwal et al., 2016).
Type III EMT is involved in cancer progression and metastatic pro-
cesses. Type III EMT is characterized by a phenotypical change of sec-
ondary epithelial cells into carcinoma cells with a high degree of
migratory and invasive properties and malignant growth subsequently
creating a novel tumour nodule (Kim et al., 2017). Tight junctions play
an important role in type III EMT; particularly, E‐cadherin down‐
regulation leads to a loss of cell–cell adhesion and thus facilitates migra-
tion and colonization of cancer cells (Rout‐Pitt, Farrow, Parsons, &
Donnelley, 2018; Thiery et al., 2009). A recent study in A549 lung can-
cer cells demonstrated that the novel TGF‐β1 inhibitor compound 67
inhibited TGF‐β1‐induced down‐regulation of E‐cadherin mRNA and
up‐regulation of N‐cadherin mRNA, with findings further confirmed
on the protein level by using immunofluorescence (Jeong et al., 2019).
The authors also reported that compound 67 reduced transmigration
through TGF‐β1‐induced layer of ECM and in turn reduced matrigel
invasion (a process commonly referred to as wound healing; Jeong
et al., 2019). These findings highlight the importance of inhibiting the
TGF‐β1 pathway in EMT and the necessity to comprehensively under-
stand the subtle cellular alterations in the distinct stages of EMT.3 | POTENTIAL ROLE OF EMT IN COPD
As outlined above, EMT plays a vital role during organ fibrosis (Kalluri &
Neilson, 2003; Kim et al., 2006; Zeisberg & Neilson, 2009), including
pulmonary fibrosis (Chapman, 2011; Kim et al., 2006). In this regard,
there is increasing interest in understanding the role of EMT in COPD
as well. COPD represents a major global health problem with the ail-
ment estimated to become the third leading cause of death and the fifth
leading cause of disability by 2030 (Barnes et al., 2015; Laudette, Zuo,
Lezoualc'h, & Schmidt, 2018). Cigarette smoke is implicated as the
primary cause of COPD.However, factors like exposure to indoor pollu-
tion frombiomass fuels and outdoor air pollution including occupational
dusts particularly in developing countries also seem to contribute to
disease progression (Barnes et al., 2015; Maji, Dikshit, Arora, &
Deshpande, 2018; Vogelmeier et al., 2017; Wang et al., 2018).
Sohal et al. (2010) reported on fragmentation of the reticular base-
ment membrane in large airways from endobronchial biopsies of
smokers, and the findings positively correlated with the subjects'
smoking history. Similar observationswere reported fromanother study
by comparing current smokers and ex‐smokers suffering from COPD,
with healthy non‐smokers (Soltani et al., 2010). Intriguingly, using
immunohistochemical staining for bronchial biopsy sections, it was
demonstrated that the fibroblast protein marker S100A4 was signifi-
cantly increased in cells within the reticular basement membrane clefts
of smokers and COPD patients as compared with never‐smoking con-
trol subjects (Sohal et al., 2010). This findingwas further confirmedwith
S100A4 and vimentin double staining, thereby indicating an active EMT
process in the large airway of CODP patients. These findings were
strongly correlated with cigarette smoke exposure (Sohal et al., 2010).
In addition, Wang, Wang, Zhang, Zhang, and Xiao (2013) assessed theexpression of the epithelial marker E‐cadherin and the mesenchymal
marker vimentin in small airway epithelium from non‐smokers, smokers,
non‐smokers with COPD, and smokers with COPD. Compared with
non‐smokers, a dramatic increase of vimentin positive cells was
detected in the small airway epithelium from smokers and COPD sub-
jects, together with a marked decrease of E‐cadherin, thereby suggest-
ing an active EMT process in small airway epithelium during the
pathogenesis of cigarette smoke‐induced COPD (Wang et al., 2013).
Even though EMTwas found to be active in both large and small airways
from COPD patients with chronic airflow limitation, EMT observed in
small airways was uniformly less than that in large airways, thereby
implying different mechanisms of EMT in small airways as compared
with large airways (Mahmood et al., 2015). In small airways, it was con-
sidered as type II EMT (profibrotic, see above) rather than as type III
EMT (malignancy associated, see above). This distinction was primarily
based on the virtual lack of hypervascularization as studied by staining
for type IV collagen (Mahmood et al., 2015).
The presence of EMT in COPD has been further identified in in vitro
cell models. Compared with primary human bronchial epithelial cells
from healthy controls, cells from COPD patients showed an up‐
regulation of mesenchymal markers (α‐SMA, collagen type I, vimentin,
and NOX4) and a down‐regulation of epithelial markers (E‐cadherin,
ZO‐1, KRT5, and KRT18), suggesting that EMT was significantly
increased in COPD patients (Milara, Peiró, Serrano, & Cortijo, 2013).
Additionally, it was demonstrated that cigarette smoke activated the
EMT process in isolated primary epithelial cells (Milara et al., 2013;
Milara et al., 2014; Wang et al., 2013), findings which are in line with
studies in epithelial cell lines such as A549 and BEAS‐2B (Eurlings
et al., 2014; Shen et al., 2014). Indeed, BEAS‐2B cells, primary normal
human bronchial epithelial cells and (rat) alveolar cells, were able to
undergoEMTprimarily induced byTGF‐β1, indicating that at least these
lung epithelial cells retained the potential to transform into mesenchy-
mal cells (Kamitani et al., 2011; Molloy et al., 2008; Willis et al., 2005).
EMT can be induced by environmental stresses or factors such as
ROS. ROS have been implicated in COPD progression and exacerba-
tions known as episodes of acute worsening of disease symptoms
(Antus & Kardos, 2015; Bernardo, Bozinovski, & Vlahos, 2015;
Kirkham & Barnes, 2013). Milara et al. (2013) demonstrated that
preincubation of differentiated primary human bronchial epithelial
cells with the antioxidants N‐acetyl‐L‐cysteine and apocynin inhibited
cigarette smoke‐induced up‐regulation of mesenchymal markers (α‐
SMA, vimentin, and collagen type I) and down‐regulation of epithelial
markers (E‐cadherin, ZO‐1, KRT5, and KRT18) both mRNA and pro-
tein. These findings were further confirmed in a knockout mouse
model of the transcription factor Nrf2 , a key regulator in the antioxi-
dant defence system known to protect against oxidative stress (Zhou
et al., 2016). Compared with wild‐type mice instilled with bleomycin,
vimentin, α‐SMA, and collagen were further and significantly aug-
mented in Nrf2‐knockout mice, whereas E‐cadherin protein was
reduced, albeit not significantly (Zhou et al., 2016).
Another important process that is involved in EMT in COPD but far
from being completely understood is the interaction between fibro-
blasts and epithelial cells. To gain more mechanistic insights, a recent
ZUO ET AL. 2405BJPstudy investigated the potential of conditioned medium derived from
normal human lung fibroblasts and COPD human lung fibroblasts in
inducing EMT in normal human bronchial epithelial cells and COPD
human bronchial epithelial cells (Nishioka et al., 2015). Exposure of both
normal and COPD human bronchial epithelial cells to conditioned
medium from normal human lung fibroblasts induced vimentin mRNA,
whereas N‐cadherin mRNA increased only in COPD human bronchial
epithelial cells, indicating that COPD human bronchial epithelial cells
had partly undergone EMT (Nishioka et al., 2015). In addition, normal
human bronchial epithelial cells exposed to COPD human lung
fibroblasts‐conditioned medium showed up‐regulation of E‐cadherin,
N‐cadherin, and vimentin protein, thereby confirming that COPD
human lung fibroblasts‐conditioned medium promoted EMT in normal
human bronchial epithelial cells (Nishioka et al., 2015). The results from
Nishioka and colleagues revealed that the interaction between fibro-
blasts and epithelial cells plays a crucial role in the EMT process in
COPD, and future studies ought to unravel the molecular nature of this
interaction.
As key effector cells during fibrosis, the accumulation of myofi-
broblasts may occur as a consequence of transition of resident fibro-
blasts to myofibroblasts, as a transition of airway smooth muscle
cells to myofibroblasts, as a transition of epithelial cells to fibroblasts
(and subsequently to myofibroblasts), or as a consequence of the
recruitment of circulating fibroblastic stem cells (Karvonen et al.,
2013; Milara et al., 2013; Scotton & Chambers, 2007). TGF‐β1
induced the transition of primary pulmonary fibroblasts from individ-
uals with COPD to myofibroblasts, a process positively correlated with
the severity of COPD (Baarsma et al., 2011). In addition, Karvonen
et al. (2013) reported recently that (α‐SMA‐positive) myofibroblasts
were variably localized in lungs from non‐smokers, smokers without
COPD, and smokers with COPD, further suggesting that this cell type
is linked to both lung regeneration and COPD development. Further
investigation, however, is necessary in order to establish the extent
to which EMT‐derived myofibroblasts contribute to fibrosis in COPD
as current findings strongly indicate that distinct stages of EMT are
active in airways of COPD patients and that cigarette smoke exposure
and oxidative stress may play vital roles during this process.4 | COMPARTMENTALIZATION OF cAMP
Research on cyclic nucleotides was initiated early in 1953 by Earl
Sutherland (Berthet, Rall, & Sutherland, 1957). For the past 60 years,
the importance of cyclic nucleotides has been elucidated, resulting in
more than five distinguished Nobel Prizes (Beavo & Brunton, 2002),
including one that was awarded in 2012 to Robert J. Lefkowitz and
Brian K. Kobilka for their contribution in unravelling the molecular
topography of the β2‐adrenoceptor (Chung et al., 2011; Lefkowitz,
Roth, & Pastan, 1970; Lefkowitz, Roth, Pricer, & Pastan, 1970;
Rasmussen, Choi, et al., 2011; Rasmussen, DeVree, et al., 2011),
strongly pointing to the importance of fundamental research to
unravel the distinct molecular mechanisms underlying the signalling
properties of cAMP.Compartmentalization, a key feature of cAMP signalling, allows
extracellular signals to propagate into the cells along defined and spe-
cific pathways within the network. Stimulation of prototypical Gs‐pro-
tein‐coupled receptors, such as the β2‐adrenoceptor and distinct
prostanoid receptors, leads to the activation of adenylyl cyclases
(ACs), which catalyse the synthesis of cAMP from ATP. cAMP is able
to exert such diverse signalling properties by activating distinct effec-
tors, which include PKA (Taylor, Knighton, Zheng, Ten Eyck, &
Sowadski, 1992), the exchange proteins directly activated by cAMP
(Epacs; Schmidt, Dekker, & Maarsingh, 2013), cyclic nucleotide‐
gated ion channels (Biel & Michalakis, 2009; Kaupp & Seifert, 2002),
and the most recently defined novel class of three‐pass transmem-
brane popeye domain‐containing proteins, which bind cAMP with a
high affinity (Schindler & Brand, 2016). The intracellular concentration
of cAMP is spatially and temporally controlled by PDEs, a superfamily
of metallohydrases that hydrolyse cAMP to AMP and thereby termi-
nate its signalling properties (Omori & Kotera, 2007). Additionally,
the AKAPs, a group of structurally diverse proteins localized at specific
subcellular sites, play a critical role in maintaining subcellular cAMP
compartmentalization by generation of spatially discrete signalling
complexes that create local gradients of cAMP (Beene & Scott,
2007; Skroblin, Grossmann, Schäfer, Rosenthal, & Klussmann, 2010).
In addition to anchoring cAMP effectors such as PKA to distinct sub-
cellular complexes, AKAPs also bind PDEs, phosphatases (which termi-
nate phosphorylation), thereby contributing to spatial regulation of
local and specific cAMP cellular processes.4.1 | Players of cAMP compartmentalization:
AKAPs, PKA, and Epac
Members of the AKAPs family bind to the regulatory subunits of PKA
and target PKA to discrete sites or macromolecular complexes,
thereby playing a central role in the regulation of cAMP compartmen-
talization. In addition, compartmentalization of cAMP signalling by
AKAP proteins plays a central role in pathological cellular responses,
primarily due to the fact that the expression level of AKAPs is subject
to profound changes under disease conditions (Poppinga, Muñoz‐
Llancao, González‐Billault, & Schmidt, 2014; Tröger, Moutty, Skroblin,
& Klussmann, 2012). It was reported recently that the mRNA of both
AKAP5 and AKAP12 was reduced in the lung tissue of COPD patients,
compared with lung tissue from controls (Poppinga et al., 2014). Sim-
ilar findings were obtained in primary airway smooth muscle cells
exposed to cigarette smoke (Poppinga et al., 2015). Because both
AKAP5 and AKAP12 have been implicated in the recycling of β2‐
adrenoceptors (see Poppinga et al., 2014), alterations in their expres-
sion profile under disease pressure (as shown in lung tissue from
COPD patients) may alter the mode of action of β2‐adrenoceptor ago-
nists. Such findings should be envisioned in the context of the current
treatment regime of COPD, which relies mainly on bronchodilator
therapy (β2‐adrenoceptor agonists, anticholinergics, and theophylline)
and on PDE4 inhibitors used in concert with either corticosteroid or
bronchodilator treatment especially in COPD patients with a high risk
2406 ZUO ET AL.BJPof exacerbations (Barnes et al., 2015; Maji et al., 2018; Vogelmeier
et al., 2017; Wang et al., 2018). This hypothesis, however, still remains
to be elucidated in additional COPD patient cohorts and/or additional
experimental models of COPD. Previously, studies focused on the role
of AKAPs in the airway epithelium. Exposure of human bronchial epi-
thelial 16HBE14o− cells to cigarette smoke extract reduced the epi-
thelial barrier, a process accompanied by a reduction of E‐cadherin
and AKAP9 both of which colocalize at the cell membrane. Interest-
ingly, E‐cadherin, but not AKAP9, protein expression was reduced in
lung tissue from COPD patients, compared with controls. However,
AKAP9 mRNA expression was decreased in primary bronchial epithe-
lial cells from current smokers as compared with non‐smokers or ex‐
smokers (Oldenburger, Poppinga, et al., 2014). The results pointed to
a divergence between AKAP9 protein expression and mRNA expres-
sion potentially reflecting functional differences in the effects of
E‐cadherin and AKAP9 on distinct EMT phenotypes. Taken together,
the findings outlined above point to an alteration of the expression
profile and subsequent change in function of some members of the
AKAP family in experimental models of COPD.
The major cAMP effectors are PKA and Epac, which can act in con-
cert or alone in several physiological processes. The guanine nucleotide
exchange factor Epac family consists primarily of two members, Epac1
(cAMP‐GEF‐I) and Epac2 (cAMP‐GEF‐II), which are able to activate
Ras‐like small GTPases. Epac proteins are known to regulate numerous
biological responses, including but not limited to inflammation, cell pro-
liferation, remodelling, and barrier functions (Grandoch, Roscioni, &
Schmidt, 2010; Insel et al., 2012; Robichaux & Cheng, 2018; Schmidt
et al., 2013). Exposure of airway smoothmuscle cells to cigarette smoke
extract reduced the protein expression of Epac1, but not Epac2, a pro-
cess involving miRNA‐7. In addition, miRNA‐7 was increased in bron-
chial smooth muscle of COPD stage II patients isolated by laser
dissection, as compared with controls (Oldenburger, van Basten, et al.,
2014). In lung tissue from COPD patients, Epac1 protein expression
was also reduced. The loss of Epac1 was associated with a higher
degree of neutrophilic inflammation measured by an increase in
NF‐κB‐dependent production of IL‐8 (Oldenburger et al., 2012). In
Epac1‐deficient mice, higher levels of TGF‐β1 (mRNA), collagen I, and
fibronectin (both mRNA and protein levels) were observed
(Oldenburger, Timens, et al., 2014). In line with these findings, it has
been reported that binding of Epac1 to the activated TGF‐β1 type I
receptor subsequently decreased the phosphorylation of Smad2 and
Smad2‐dependent transcription (Conrotto, Yakymovych, Yakymovych,
& Souchelnytskyi, 2007), raising the possibility that Epac1 may poten-
tially inhibit the production of collagen by binding to the TGF‐β1 type
I receptor. Given the fact that cigarette smoke is one of the main
inducers of COPD (Barnes et al., 2015; Maji et al., 2018; Vogelmeier
et al., 2017; Wang et al., 2018), the findings outlined above point to a
link between COPD and an impaired Epac1 signalling. As it is generally
accepted that local inflammation contributes toTGF‐β1‐induced EMT,
impaired Epac1 signalling may not only cause a higher deposition of
ECM but may also worsen the process of chronic inflammation.
Because Epac2 seems to act in a proinflammatory manner in lung tissue
(Oldenburger, Timens, et al., 2014), Epac1 and Epac2may cooperativelyregulate the process of EMT induced by TGF‐β1. The development of
Epac1‐ and Epac2‐specific inhibitors from 2012 onwards continues to
foster research in this area (Parnell, Palmer, & Yarwood, 2015;
Robichaux & Cheng, 2018; Schmidt et al., 2013). Studies in airway
smooth muscle cells exposed toTGF‐β1 induced the de novo synthesis
of ECM components, such as collagen types I, III, and IV, and fibronectin
(Lambers et al., 2014). Treatment with long‐acting β2‐adrenoceptor
agonists (formoterol and salmeterol) exclusively prevented the
TGF‐β1‐induced de novo synthesis of a distinct subset of ECM compo-
nents, specifically type I and type III collagen. Using the P‐site AC inhib-
itor 2′‐5′‐dideoxyadenosine, the authors reported on the intriguing
finding that the de novo synthesis of ECM components distinctly
depends on cAMP, suggesting that specific cAMP scaffolds are most
likely operational in these structural lung cells (Lambers et al., 2014). It
will therefore be of interest in the future to study the extent to which
distinct ACs (Halls & Cooper, 2017), acting in concert with a distinct
subset of PDEs, PKA, and Epac, may contribute to the differential regu-
lation of ECM deposition. Even though such cAMP microdomains have
been extensively studied in the cardiovascular system (Laudette et al.,
2018; Musheshe, Schmidt, & Zaccolo, 2018), they still have to be
defined in more detail in the pulmonary system.
4.2 | Players of cAMP compartmentalization: PDE
The superfamily of PDEs comprises 11 family members and at least 21
isoforms with different splice variants (Page & Spina, 2012). PDEs
hydrolyse cyclic nucleotides (cAMP and cGMP) to their respective inac-
tive 5′‐monophosphates within subcellular microdomains, thereby
leading to an organization of cyclic nucleotides signalling in time and
space. PDE4, PDE7, and PDE8 are specific for cAMP, and particularly,
PDE4 is the most widely studied PDE isozyme being evidently linked
to compartmentalization of cAMP and thus to cellular signalling and
adaptation (Conti et al., 2003; Manganiello, 2002). Oral administration
of the PDE4 inhibitor roflumilast (1 or 5mg·kg−1) prevented lung paren-
chyma destruction induced by cigarette smoke exposure for 5 days per
week for 7 months in mice (Martorana, Beume, Lucattelli, Wollin, &
Lungarella, 2005; Figure 2). These results point to PDE4 inhibition as a
potential player in the prevention of lung tissue remodelling in experi-
mental models of COPD. Also, these findings suggest that roflumilast
acted by inhibiting the activation and recruitment of macrophages,
which in turn prevented parenchymal destruction induced by chronic
cigarette smoke exposure through a reduced release of metallo-
proteases frommacrophages. In concert with these findings, Martorana
et al. (2005) observed a reduced macrophage density in mice treated
with roflumilast. Persistent inflammation is linked to a distinct subset
of EMT; therefore, the prevention of inflammation by the PDE4 inhibi-
tor might be of benefit for different phenotypes of EMT.5 | cAMP COMPARTMENTALIZATION IN
EMT
The process of EMT is driven by a complex regulatory network
beyond the transcriptional level, which integrates epigenetics,
FIGURE 2 The role of cAMP scaffolds in
TGF‐β‐induced epithelial‐to‐mesenchymal
transition (EMT) in the lung. cAMP, which
localizes in specific subcellular microdomains,
modulates the activities of downstream
effectors PKA and Epacs. PDEs, central
players in spatio‐temporal dynamics,
hydrolyse cAMP and prevent it from diffusing
to other compartments. Expression of PDE4
and PDE8 mRNA expression is significantly
up‐regulated by TGF‐β1. A‐kinase anchoring
proteins (AKAPs) are a group of scaffolding
proteins with the ability to associate with PKA
via a short α‐helical structure. Ezrin is
associated with PGE2‐induced β‐catenin
transcription. AKAP9 plays a crucial role in E‐
cadherin maintenance. AKAP13, known to act
as a guanine nucleotide exchange factor for
RhoA, may be able to promote αvβ6 integrin‐
mediated TGF‐β activation in response to
epithelial injury. As main inducing factors,
cigarette smoke and air pollution are able to
modulate cAMP scaffolds in the lung
structural cells. For further details, see text.
β2‐AR, β2‐adrenoceptor; EP2, prostanoid EP2
receptor
ZUO ET AL. 2407BJPalternative splicing, protein stability, and most importantly subcellular
localization (Jolly et al., 2017; Nieto, 2011). Several lines of evidence
indicate that cAMP—a central player in compartmentalized signalling
—acts as a potential novel pharmaceutical target in EMT (Kolosionek
et al., 2009; Milara et al., 2014; Table 1).TABLE 1 The role of cAMP compartmentalization during the process of
Protein family Subfamily/isoform Effect in EMT‐linked proce
AKAP Ezrin Morphological changes, act
and cell migration and in
Increased metastatic poten
Actin stress fibre assembly
transition
AKAP9 Cancer development and m
Ezrin/radixin/moesin Actin cytoskeleton remode
AKAP13






PDE4 PDE4 inhibition restores ep
inhibits mesenchymal ma
of EMT induced by cigar
PKA and EPAC Epac1 Increased RNA expression
induced EMT
PKA PKA‐selective cAMP agonis
α‐SMA elevation by TGF
Note: AKAP: A‐kinase anchoring protein; EMT: epithelial‐to‐mesenchymal trans5.1 | The role of AKAP proteins in EMT
The membrane–cytoskeleton linker AKAP, ezrin, plays a crucial role in
cell migration and invasion by regulating the assembly of cytoskeleton




Chen et al. (2014)
tial Huang et al. (2010), Jansen et al. (2016),
and Li et al. (2012)
and morphological Haynes, Srivastava, Madson, Wittmann,
and Barber (2011)
etastasis of cancers Frank et al. (2008), Kabbarah et al. (2010),
and Truong et al. (2010)
lling Tsukita and Yonemura (1999)
pathic pulmonary Allen et al. (2017)




Kolosionek et al. (2009) and
Milara et al. (2014)
in PGE2‐ Jansen et al. (2016)
t reduces
‐β1
Insel et al. (2012)
ition; α‐SMA: α‐smooth muscle actin.
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Louvard, & Arpin, 2005; Ohtani et al., 1999). In human alveolar epithe-
lial cells, ezrin is highly associated with morphological changes, actin
filament remodelling, and regulation of cell migration and invasion in
EMT induced by TGF‐β1 (Chen et al., 2014; Figure 2). Moreover, in
tumour‐related studies, overexpression of ezrin enhanced the meta-
static potential, whereas the knockdown of ezrin inhibited cell migra-
tion and invasion (Huang et al., 2010; Jansen et al., 2016; Li et al.,
2012). Interestingly, ezrin altered its intracellular localization from
the apical membrane to the cytoplasm in lung cancers, thereby indicat-
ing that subcellular compartmentalization of ezrin is subject to alter-
ations during cancer progression (Li et al., 2012). In asthma, ezrin
protein expression was significantly decreased in exhaled breath con-
densate and serum from asthma patients as compared with normal
subjects (Jia et al., 2018). These findings were further confirmed in
IL‐13‐stimulated human bronchial epithelial 16HBE cells and
ovalbumin‐treated allergic mouse model (Jia et al., 2018), indicating
that ezrin is most likely involved in the pathogenesis of asthma.
Twhe actin‐binding proteins, ezrin, radixin and moesin (ERM) are
known to organize the cortical cytoskeleton by linking filamentous actin
to the apical membrane of cells (Neisch & Fehon, 2011; Schmidt et al.,
2013; Tsukita & Yonemura, 1999). Studies in mouse mammary gland
epithelial cells showed that althoughTGF‐β1 up‐regulated the expres-
sion of moesin, ezrin expression was down‐regulated, whereas that of
radixin remained unchanged (Haynes et al., 2011). Additionally, cells,
whose moesin expression was suppressed by short hairpin RNA, had
dramatically fewer actin stress fibres, and the bundled filaments were
thinner and shorter, compared with those in control cells, further indi-
cating that moesin promoted actin stress fibre assembly and morpho-
logical transition during TGF‐β1‐induced EMT (Haynes et al., 2011).
The distinct changes in the expression of ERMproteins during the initial
stages of TGF‐β1‐induced EMT suggest that ERM proteins may differ-
entially contribute to distinct EMT phenotypes. However, the function
of ERM proteins is yet to be elucidated in lung epithelial cells.
It has been reported previously that AKAP9 is involved in the
development and metastasis of cancers such as breast cancer, lung
cancer, and melanomas (Frank et al., 2008; Kabbarah et al., 2010;
Truong et al., 2010). Although further evidence has to be provided
that AKAP9 plays a key role in regulating EMT in the lung, findings
in colorectal cancer Lovo cells exposed to TGF‐β1 indicated that
knockdown of AKAP9 expression using short hairpin RNA restored
E‐cadherin expression and in contrast attenuated N‐cadherin and
vimentin expression, suggesting that AKAP9 may play an important
role in TGF‐β1‐induced EMT (Hu et al., 2016; Figure 2).
Recently, Allen et al. (2017) studied 2,760 patients with idiopathic
pulmonary fibrosis (IPF) and 8,561 controls, and they identified a novel
genome‐wide significant association of variant rs62025270 of
AKAP13 as a susceptibility gene for IPF. Using immunohistochemical
staining, it was reported that AKAP13 protein was primarily expressed
in bronchial epithelium and alveolar type 1 and 2 cells in control lung
tissue, whereas in lung tissue from IPF patients, high AKAP13 expres-
sion was detected in fibrotic regions. Additionally, a substantial higher
AKAP13 expression was observed in alveoli of patients with IPF ascompared with controls (Allen et al., 2017). Likewise, AKAP13 mRNA
expression was 1.42 times higher in lung tissue from patients with IPF,
compared with controls (Allen et al., 2017). It has been suggested that
AKAP13, known to act as a guanine nucleotide exchange factor for
RhoA, might be able to promote αvβ6 integrin‐mediated TGF‐β acti-
vation in response to epithelial injury, suggesting that AKAP13 may
be associated with the pathogenesis of the EMT process (Diviani,
Soderling, & Scott, 2001; Jansen et al., 2018; Jenkins et al., 2006;
Majumdar, Seasholtz, Buckmaster, Toksoz, & Brown, 1999; Xu et al.,
2009). In addition, AKAP13 seems to target the prostaglandin endo-
peroxide synthase and might provide a molecular link between the
cAMP and the EMT process (Table 1).5.2 | The role of PDE family members in EMT
Although it has been reported that PDE1–PDE8 subtypes are highly
expressed in lung epithelial cells (Fuhrmann et al., 1999; Haddad
et al., 2002; Page & Spina, 2012; Zuo et al., 2018), the precise role
of the distinct PDEs in the diverse functions of epithelial cells is still
unclear. In A549 cells, TGF‐β1 treatment resulted in a significant
increase in gene expression of PDE4A, PDE4D, and PDE8A, whereas
the gene expression of PDE1A, PDE3A, and PDE7B was decreased
(Kolosionek et al., 2009). Among the up‐regulated PDE isoforms,
PDE4D showed the most prominent increase in mRNA (Kolosionek
et al., 2009). Additionally, the PDE4‐specific inhibitor rolipram
restored the expression of the epithelial marker E‐cadherin and
abolished up‐regulation of the mesenchymal markers fibronectin and
collagen I (both mRNA and protein) by TGF‐β1. These findings were
further confirmed by using siRNA targeting PDE4A and PDE4D
(Kolosionek et al., 2009). In another separate study, Milara et al.
(2015, 2014) reported that roflumilast N‐oxide, the active metabolite
of the PDE4 inhibitor roflumilast, prevented cigarette smoke‐induced
EMT in differentiated human bronchial epithelial cells by restoration
of the loss of intracellular cAMP after cigarette smoke exposure
(Figure 2). These studies emphasized the importance of PDE4 inhibi-
tion in blocking the EMT process induced by either TGF‐β1 or ciga-
rette smoke. Additional investigation is needed however to further
characterize the distinct role of other PDE family members in EMT
phenotypes in the lung.5.3 | The role of PKA and Epac in EMT
PKA and Epac are two of the best known downstream effectors of
cAMP. There are two Epac isoforms, Epac1 and Epac2, which have dis-
tinct tissue expression patterns (Schmidt et al., 2013). Studies have
demonstrated that gene expression of Epac1 but not Epac2 was
increased by PGE2 in lung epithelial A549 cells (Jansen et al., 2016),
thereby emphasizing that Epac1 was involved in PGE2‐induced EMT.
It has been shown that PGE2 is able to induce EMT and enhance cell
migration by augmenting ZEB1 and suppressing E‐cadherin expression
in non‐small cell lung carcinoma, which is associated with stabilization
of β‐catenin and activation of β‐catenin‐dependent transcription
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More importantly, cotreatment of A549 cells with the Epac1 inhibitor
CE3F4 or down‐regulation of Epac1 expression with siRNA fully
abolished the induction of cell migration by PGE2. Moreover, ezrin
knockdown prevented PGE2‐induced β‐catenin transcriptional activ-
ity, indicating that the scaffold protein ezrin acts as a physical link
between β‐catenin and Epac1 (Jansen et al., 2016).
Interestingly, another PG. PGD2, has been reported to inhibit
TGF‐β1‐induced EMT in MDCK cells. In addition, PKA inhibition by
H89 was able to block the inhibitory effect of AC activator forskolin
on TGF‐β1‐induced EMT, whereas inhibition of endogenous cAMP
activity via H89 had no effect of PGD2‐induced inhibition of EMT
(Zhang, Dong, & Yang, 2006). In additional studies in MDCK cells, i
8‐Me‐cAMP—a cAMP derivative that selectively activates Epac but
not N6‐cAMP—a PKA‐selective cAMP agonist, blunted the TGF‐β1‐
induced up‐regulation of α‐SMA. In contrast, both 8‐Me‐cAMP and
N6‐cAMP reversed the TGF‐β1‐induced E‐cadherin down‐regulation
(Insel et al., 2012). Taken together, these data indicate that both
PKA and Epacs are involved in EMT, although their particular contri-
bution may differ depending on distinct cAMP pools that are
activated.6 | OUTLOOK AND FUTURE PERSPECTIVES
As one of the best known second messengers, cAMP transmits the
information carried by hormones, neurotransmitters, and other extra-
cellular signals into the intracellular environment (Berthet et al.,
1957; Musheshe et al., 2018). Despite a wide array of information
being unravelled about the cAMP signalling pathway, however, a num-
ber of outstanding questions still remain. It is still not clear how a sim-
ple molecule such as cAMP coordinates such a wide range of
physiological and pathophysiological processes; why cAMP accumula-
tion induced by stimulation of different Gs‐protein‐coupled receptors
evoke distinct cell type‐specific responses; why β2‐adrenoceptor ago-
nists cause airway smooth muscle relaxation but have no clinically rel-
evant effects on airways inflammation or airway remodelling; why
PDE3 inhibitors are able to relax airway smooth muscle, yet they are
not anti‐inflammatory; why PDE4 inhibitors act as anti‐inflammatory
drugs but have no acute bronchodilator effects; and lastly, why theo-
retically PDE4 inhibitor roflumilast provides clinically relevant effects
in patients with COPD, yet the development of various inhalable
PDE4 inhibitors has been halted due to lack of efficacy. These out-
standing questions need to be addressed urgently to further enhance
understanding of cAMP research in the lung. Comprehensive under-
standing of the spatio‐temporal dynamics of cAMP compartments will
provide a platform for unravelling the distinct cAMP signalling proper-
ties and for screening of novel therapeutic agentss with higher effica-
cies and less side effects for the treatment of obstructive lung
diseases.
As one of the main bronchodilator therapies, β2‐adrenoceptor ago-
nists augment the anti‐inflammatory effects of corticosteroids in
obstructive lung diseases (Barnes et al., 2015; Maji et al., 2018;Vogelmeier et al., 2017; Wang et al., 2018). Even though it has been
shown that the β2‐adrenoceptor agonists inhibited cytokine release
in vitro (Bosmann et al., 2012; Hallsworth, Twort, Lee, & Hirst, 2001;
Poppinga et al., 2015), evidence for their anti‐inflammatory properties
in vivo is still lacking (Giembycz & Maurice, 2014; Giembycz &
Newton, 2006). Potential explanations for lacking evidence in vivo
may be due to the development of β2‐adrenoceptor desensitization,
followed by receptor internalization (Charlton, 2009; Dekkers, Racké,
& Schmidt, 2013; Giembycz & Newton, 2006) and due to the fact that
the β2‐adrenoceptor agonists induced biased signalling via β‐arrestin‐
2, subsequently leading to airway hyperresponsiveness and inflamma-
tion (Nguyen et al., 2017; Walker, Penn, Hanania, Dickey, & Bond,
2011). Another unresolved issue that needed to be addressed in the
field of compartmentalized cAMP signalling was the controversial
effects of PDE3 inhibition on airway hyperresponsiveness and inflam-
mation. It has been proven that PDE4 inhibition effectively reduces
activation and recruitment of inflammatory cells and reduces the
release of various cytokines and the production of ROS. This charac-
teristic of PDE4 inhibitors is most likely due to the fact that PDE4 is
widely expressed in inflammatory and immune cells (Barber et al.,
2004; Engels, Fichtel, & Lübbert, 1994). Despite PDE3 being present
in T lymphocytes, it has a limited impact on T‐cell proliferation and
cytokine production (Giembycz, Corrigan, Seybold, Newton, & Barnes,
1996). Recently, Beute et al. (2018) studied the role of PDE3A and
PDE3B in inflammation using an acute house dust mite (HDM)‐driven
allergic airway inflammation mouse model. The number of eosinophils,
T lymphocytes, neutrophils, and macrophages in bronchoalveolar
lavage fluid was significantly decreased in HDM‐treated PDE3A−/−
mice and PDE3B−/− mice as compared with wild‐type mice. Moreover,
the proportion of IL‐5‐ and IL‐13‐positive CD4+ T cells in bronchoal-
veolar lavage fluid was significantly decreased in HDM‐treated
PDE3A−/− and PDE3B−/− mice compared with wild‐type mice, sug-
gesting that PDE3 may act as a novel anti‐inflammatory target in aller-
gic airway inflammation (Beute et al., 2018). Regarding
bronchodilation, a substantial body of evidence shows that PDE3
inhibitors (siguazodan, SK&F94120, and org9935) are potent relaxants
in airway smooth muscle (Bernareggi, Belvisi, Patel, Barnes, &
Giembycz, 1999; Nicholson et al., 1995; Torphy et al., 1993), while
contrasting findings are reported regarding PDE4 inhibition in various
animal models. Such differences may be explained by differential
expression patterns of PDE4 in airway smooth muscle cells from var-
ious species (Zuo et al., 2018). Oral administration of roflumilast, a
PDE4 inhibitor, has been approved for the treatment of severe COPD
patients associated with bronchitis and with a history of frequent
exacerbations. However, side effects still limit the extensive usage of
PDE4 inhibitors (Giembycz & Maurice, 2014). A strategy to overcome
the side effects is to deliver the drugs by inhalation; however, none of
the very potent inhaled PDE4 inhibitors (GSK256066 and CHF6001)
have shown any convincing evidence of efficacy in the treatment of
respiratory diseases so far, thereby suggesting that the clinical benefits
of PDE4 inhalation may arise from systemic effects.
The field of compartmentalized cAMP signalling may also offer
answers to yet unresolved questions underlying the distinct stages
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responses. Certainly, EMT plays a vital role during organ fibrosis,
including pulmonary fibrosis (Jolly et al., 2018; Rout‐Pitt et al.,
2018). In addition, accumulating evidence indicates that an active
EMT process is operational in experimental models of COPD, asthma,
and IPF. Recent evidence also indicates that cAMP scaffolds main-
tained by a diverse subset of receptors, PDEs, PKA, Epac, and mem-
bers of the AKAP superfamily have the potential to target distinct
aspects of the EMT process, with the EMT process being closely
related to factors such as TGF‐β1, TNF‐α, and/or IL‐13. Intriguingly,
Jia et al. (2018) reported recently that the expression of the AKAP
family member ezrin is closely related to the severity of asthma. The
loss of ezrin correlated with the IL‐13‐induced damage of bronchial
epithelial cells in both patients and experimental models of asthma,
suggesting that ezrin may serve as a potential biomarker to control
asthma (Jia et al., 2018). Similarly, expression of ezrin was subject to
alterations in both airway smooth muscle exposed to cigarette smoke
and lung tissue from COPD patients (Poppinga et al., 2015), implying
that ezrin plays a crucial role in obstructive lung diseases. In addition,
ezrin directly interacted with Epac1 and promoted the nuclear translo-
cation of β‐catenin (Jansen et al., 2016). These findings indicated that
cAMP scaffolds encompassing ezrin and Epac1 have the potential to
initiate the canonical β‐catenin‐dependent signalling of Wnt recep-
tors, with Wnt signalling being known to play an important role in pro-
moting epithelial repair (Skronska‐Wasek, Gosens, Königshoff, &
Baarsma, 2018). Ezrin acts as a regulator for the Rho signalling path-
way, a pathway that regulates cell migration, phenotypical alterations,
and metastatic cellular potential (Jansen et al., 2016) and therefore
may be of central importance at different stages of the EMT process.
Another study linked the AKAP family member AKAP13 to IPF in a
process involving Rho and the prostanoid receptors (Allen et al.,
2017). To date, only a very limited number of drugs are available to
target lung fibrosis. Therefore, further studies with a special focus on
the distinct role of the AKAP family members such as ezrin and
AKAP13 will identify new therapeutic targets and hence novel drugs
in the treatment of lung fibrosis (Gourdie, Dimmeler, & Kohl, 2016;
Kalluri, 2016; Mora, Rojas, Pardo, & Selman, 2017).7 | CONCLUSIONS
Potential links between diverse lung disorders such as asthma, COPD
and IPF might be represented by oxidative stress and air pollution.
Oxidative stress, either induced by inflammatory cells or by inhaled
noxious compounds, is an important player in the pathophysiology of
these obstructive lung disorders (Anathy et al., 2018; Bernardo et al.,
2015; Comhair & Erzurum, 2010; Domej, Oettl, & Renner, 2014;
Nadeem, Masood, & Siddiqui, 2008). Air pollution is a major environ-
mental threat not only in Europe but worldwide as it represents a
global threat as far as human health and the social economic burden
in the long term. The World Health Organization (WHO) report indi-
cates that each year about 7 million people die as a result of exposure
to air pollution. Despite the decrease in air pollutants over the pastdecades, air pollutant concentrations in urbanized areas still exceed
reference values. Long‐term and peak exposure to ground level ozone,
nitrogen dioxide and particulate matter (PM) pose serious health risks,
with PM 2.5 in air being estimated to reduce life expectancy by at
least eight months. Such devastating effects are related to the hetero-
geneous nature of PM in size and composition. For instance, fine PM
from diesel exhaust represent a considerable percentage of urban PM
which contains polycyclic aromatic hydrocarbons. Certain groups of
people are identified as more susceptible to health effects due to air
pollution, and among these and of particular concern are elderly peo-
ple, children, and people with pre‐existing lung disease such as asthma
and COPD, specifically the groups suffering from exacerbations
(Annesi‐Maesano, 2017). Interestingly, it has been shown that ultra-
fine particulate matter initiates the process of EMT in BEAS‐2B cells
(Thevenot et al., 2013)—a process accompanied by a loss of
E‐cadherin and a gain in α‐SMA. Recent studies reported on alter-
ations of the expression of the AKAP member: AKAP5, AKAP12, ezrin
and AKAP9 in experimental models of COPD (Oldenburger, Poppinga,
et al., 2014; Poppinga et al., 2015), next to a change in the expression
of Epacs and PDEs (Oldenburger, Timens, et al., 2014; Zuo et al.,
2018), clearly indicating that oxidative stress alters the subcellular
composition of cAMP scaffolds. Therefore, future studies should aim
to target cAMP scaffolds either by stabilizing their composition or
modifying their composition. A better understanding of compartmen-
talized cellular cAMP signalling might further increase our knowledge
about the distinct stages of EMT phenotypes thereby bridging poten-
tial disconnections between in vitro and in vivo findings.
7.1 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corre-
sponding entries in http://www.guidetopharmacology.org, the com-
mon portal for data from the IUPHAR/BPS Guide to
PHARMACOLOGY (Harding et al., 2018), and are permanently
archived in the Concise Guide to PHARMACOLOGY 2017/18
(Alexander, Christopoulos et al., 2017; Alexander, Fabbro et al.,
2017a, Alexander, Fabbro et al., 2017b; Alexander, Kelly et al., 2017;
Alexander, Striessnig, et al., 2017).
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